Clinical trials in Chalcis

Clinical trial activity in Chalkida is focused entirely on cardiovascular diseases, with studies centered on different forms of heart failure. The research is mainly aimed at evaluating new treatment approaches that may help reduce serious heart-related events and improve symptom control.

• Heart failure with reduced ejection fraction
• HFpEF and HFmrEF linked to obesity
• Heart failure with systemic inflammation
• Testing whether new therapies can improve outcomes beyond standard care

These trials are exploring both treatment effectiveness and the potential to lower risks such as cardiovascular death, hospitalisation, and urgent care visits.

Current studies in this area are examining whether targeted therapies can better manage symptomatic heart failure in patients whose condition remains difficult to control. The focus is on improving long-term outcomes for people with more advanced forms of the disease.

• HFrEF with severely reduced ejection fraction
• Comparing a new treatment with placebo
• Assessing added benefit alongside guideline-directed medical therapy

This line of research aims to clarify whether new options can offer meaningful benefit in everyday clinical care.

Another important research theme links heart failure with systemic inflammation and obesity, reflecting growing interest in how these factors influence disease progression. The studies are designed to test whether newer therapies can address these overlapping risks more effectively.

• HFpEF and HFmrEF with obesity
• Heart failure with inflammation
• Evaluating whether treatment can reduce major cardiovascular events
• Supporting better control of complex, mixed-risk patient groups

Together, these trials reflect a focused effort in Greece to improve care for people living with challenging forms of heart failure.